Latest News

Search News
Categories
Archives
In conversation with Professor Marco Gerlinger

20th May 2022

This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.

Read more

£3.1 million for PROTECT trial

6th May 2022

Yorkshire Cancer Research has announced a £3.1 million grant for research led by Ranjit Manchanda to investigate the risks, benefits, and feasibility of introducing population-based genetic testing for ‘all’ women to find out if they are at high risk of cancer. Thousands of women living in Yorkshire and other parts of the UK will be offered tests as part of the PROTECT (Population based germline testing for early detection and cancer prevention) clinical trial.

Read more

Investigating new treatment targets for lymphoma, and beyond

5th May 2022

We spoke with Dr John Riches, Clinical Senior Lecturer in the Centre for Haemato-Oncology at Barts Cancer Institute, Queen Mary University of London, about his team’s recent publication, which describes a new potential treatment target for a subset of lymphomas.

Read more

Introducing Dr Diu Nguyen

29th April 2022

We would like to wish a very warm welcome to Dr Diu Nguyen who has recently joined the Barts Cancer Institute, Queen Mary University of London as a Lecturer and Group Leader. Dr Nguyen joins us from the Memorial Sloan Kettering Cancer Center in New York, USA, where she completed her postdoctoral training investigating the role of post-transcriptional regulation in normal and malignant cancer stem cells.

Read more

Study suggests simple blood test could help to monitor pancreatic cancer patients

28th April 2022

Researchers from Barts Cancer Institute at Queen Mary University of London have found it is possible to identify and track genetic variations in the tumours of patients with pancreatic cancer using a simple blood test.

Read more

Rewiring the biology of leukaemia cells to reverse drug resistance

20th April 2022

Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukaemia cells. By rewiring the inner workings of the cancer cells, the team was able to prime leukaemia cells for sensitivity to treatment in the laboratory.

Read more

Search News
Categories
Archives
© 2013 ~ 2022 Cancer Research UK Barts Centre